Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin A Cheever

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Immunological Reviews|March 28, 2008
Twelve immunotherapy drugs that could cure cancersMartin A Cheever
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2011
PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccineMartin A Cheever, Celestia S Higano
Journal of Immunology (Baltimore, Md. : 1950)|February 19, 2013
Pillars article: Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J. Exp. Med. 1981. 154: 952-963Philip D Greenberg, Martin A Cheever, Alexander Fefer
Vaccine|March 10, 2005
Cancer vaccines and immunotherapies: emerging perspectivesRobert A Henderson, Sally Mossman, Natalie Nairn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunityKeith L Knutson, Kathy Schiffman, Martin A Cheever, et al.
Seminars in Oncology|July 26, 2002
Designing HER2 vaccinesTeresa M Foy, Gary R Fanger, Susan Hand, et al.
Clinical Breast Cancer|March 7, 2003
HER2 dendritic cell vaccinesMichael A Morse, Timothy M Clay, Kirsten Colling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2002
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccinesMary L Disis, Theodore A Gooley, Kristine Rinn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Translational Research Working Group developmental pathway for immune response modifiersMartin A Cheever, Jeffrey Schlom, Louis M Weiner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2004
Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccineMary L Disis, Kathy Schiffman, Katherine Guthrie, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Immunological Reviews|March 28, 2008
Twelve immunotherapy drugs that could cure cancersMartin A Cheever
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2011
PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccineMartin A Cheever, Celestia S Higano
Journal of Immunology (Baltimore, Md. : 1950)|February 19, 2013
Pillars article: Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J. Exp. Med. 1981. 154: 952-963Philip D Greenberg, Martin A Cheever, Alexander Fefer
Vaccine|March 10, 2005
Cancer vaccines and immunotherapies: emerging perspectivesRobert A Henderson, Sally Mossman, Natalie Nairn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunityKeith L Knutson, Kathy Schiffman, Martin A Cheever, et al.
Seminars in Oncology|July 26, 2002
Designing HER2 vaccinesTeresa M Foy, Gary R Fanger, Susan Hand, et al.
Clinical Breast Cancer|March 7, 2003
HER2 dendritic cell vaccinesMichael A Morse, Timothy M Clay, Kirsten Colling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2002
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccinesMary L Disis, Theodore A Gooley, Kristine Rinn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Translational Research Working Group developmental pathway for immune response modifiersMartin A Cheever, Jeffrey Schlom, Louis M Weiner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2004
Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccineMary L Disis, Kathy Schiffman, Katherine Guthrie, et al.
Pageof 4